Editas Medicine Posts Q4 Revenue of $7.5M, Analysts Boost Estimates

Editas Medicine reported Q4 revenues of $7.5m, beating estimates by 53%. The company reported a statutory loss of $0.28 per share, smaller than expected. Analysts are boosting their estimates, with revenues predicted to decline 66% to $16m in 2026 and losses shrinking 50% to $1.02. The consensus price target remains at $4 despite higher revenue estimates.